AIM IMMUNOTECH INC (AIM) Stock News

USA - NYSEARCA:AIM - US00901B3033 - Common Stock

1.575 USD

+0 (+0.13%)

Last: 11/11/2025, 8:04:00 PM

1.5 USD

-0.07 (-4.76%)

After Hours: 11/11/2025, 8:04:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

AIM Latest News, Press Relases and Analysis

All

Press Releases

an hour ago - By: Benzinga - Mentions: GWRS IMRX DYAI LEGN ...

Earnings Scheduled For November 12, 2025

3 months ago - By: Benzinga

Uncovering Potential: AIM ImmunoTech's Earnings Preview

2 days ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen’s Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer

8 days ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

9 days ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen® (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue

23 days ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech to Attend the 2025 Maxim Growth Summit

a month ago - By: Zacks Investment Research

All You Need to Know About AIM ImmunoTech (AIM) Rating Upgrade to Buy

2 months ago - By: AIM ImmunoTech Inc.

AIMイムノテック (AIM ImmunoTech)、アンプリジェン (Ampligen®)(リンタトリモド) とチェックポイント阻害剤を併用する新規がん治療に関する特許を日本で2039年まで取得

2 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors

2 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth

2 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland

3 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

3 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update

3 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

3 months ago - By: Zacks Investment Research - Mentions: FGEN

FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates

3 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)

3 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval

3 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Closing of $8.0 Million Public Offering

4 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering

4 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

4 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies

5 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders’ Equity Requirements

5 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Resumes Trading on NYSE American

5 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®